endo pharma posts

Feed

Analyst upgrades, downgrades and initiations: AAPL, BAC, C, CMCSA, NOK, USB ...

Analyst upgrades:

  • UBS upgraded Apple (NASDAQ: AAPL) to Buy from Neutral and raised its target to $265 from $170, citing higher iPhone expectations, new partnerships, and likely upward revisions to Street estimates driven by gross margins.
  • Wells Fargo upgraded Comcast (NASDAQ: CMCSA) to Outperform from Market Perform. The firm views a possible deal between end General Electric's (NYSE: GE) NBC Universal positively, as it thinks NBC will provide higher-margin growth for Comcast.
  • Janney Montgomery upgraded Michael Baker (AMEX: BKR) to Buy from Neutral after the company completed the sale of its Energy business. The firm raised its target on shares to $46 from $40.
  • Jefferies assumed coverage of Endo Pharma (NASDAQ: ENDP) and upgraded the stock to Buy from Hold. The firm cites valuation, a strong base business, and solid cash flow for the upgrade, and has a $30 target price on shares.
  • Marten Transport (NASDAQ: MRTN) was upgraded to Overweight from Equal Weight at Stephens.
  • U.S. Bancorp (NYSE: USB) was upgraded to Outperform from Market Perform at Keefe Bruyette.

Continue reading Analyst upgrades, downgrades and initiations: AAPL, BAC, C, CMCSA, NOK, USB ...

Analyst upgrades 1-9-07: Cheesecake Factory takes top honors

MOST NOTEWORTHY: Armor Holdings and Cheesecake Factory were the most notable upgrades this morning.
  • Lehman Brothers upgraded Armor Holdings (NYSE: AH) to Overweight from Equal Weight, following details of the President's $100B 2007 defense budget supplemental.
  • Raymond James upgraded Cheesecake Factory (NASDAQ: CAKE) to Outperform from Market Perform following the company's better than expected forth quarter comps and revenues.

OTHER UPGRADES:
  • Shares of Novel Inc (NASDAQ: NOVL) were upgraded to Outperform from Market Perform by JMP Securities; the firm said Novell's release of Open Enterprise Server 2 may help stop declines in the combined Netware/OES product lines.
  • Jefferies upgraded shares of Endo Pharmaceuticals Hlds (NASDAQ: ENDP) to Buy from Hold, with a $35 target, to reflect improving Opana prescriptions and the resolution of the Penwest dispute, which the broker believes removes uncertainty and adds earnings visibility.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Symbol Lookup
IndexesChangePrice
DJIA-74.9212,454.83
NASDAQ-1.852,837.53
S&P 500-2.861,317.82

Last updated: May 28, 2012: 08:41 AM

Hot Stocks

General Electric

19.20-0.05(-0.26)

Alcoa

8.630.00(0.00)

Apple Inc

562.29-3.03(-0.54)

Google Inc 'A'

591.53-12.13(-2.01)

Bank of America

7.15+0.01(+0.14)

Wal-Mart Stores

65.31+0.24(+0.37)

Exxon Mobil Corp

82.08-0.53(-0.64)

Ford

10.60+0.01(+0.09)

Citigroup

26.47-0.19(-0.71)

IBM

194.30-1.79(-0.91)

Yahoo

15.36+0.01(+0.07)

Starbucks

54.56-0.20(-0.37)

Microsoft

29.06-0.01(-0.03)

Home Depot

49.44-0.27(-0.54)

DailyFinance Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

Page Loaded in 1338208869440 ms.